Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. reports developments as a global animal health company serving veterinarians, livestock producers and pet owners. Its updates center on medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for companion animals and livestock, organized commercially through U.S. and International segments.
Recurring news includes quarterly results and guidance, dividend declarations, investor conference presentations, pipeline and product-regulatory updates, and portfolio activity tied to animal health innovation. Company materials also describe R&D work across areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity, as well as approved long-acting osteoarthritis pain products Lenivia and Portela.
Zoetis Inc (NYSE:ZTS) will host a webcast and conference call on May 5, 2022, at 8:30 a.m. (ET) to discuss its first quarter 2022 financial results. CEO Kristin Peck and CFO Wetteny Joseph will lead the call. Investors can access the live webcast via the Zoetis investor website. Zoetis, the world's leading animal health company, generated $7.8 billion in revenue in 2021 and employs approximately 12,100 people globally. More details and a replay of the call will be available on the website.
Zoetis (NYSE:ZTS) will attend the Barclays Global Healthcare Conference on March 17, 2022, where Wetteny Joseph, Executive Vice President and CFO, will present at 9:30 a.m. ET. Interested investors can access a live audio webcast of the presentation at http://investor.zoetis.com/events-presentations. A replay will be available on the Zoetis website afterward. Zoetis, a leading animal health company, generated $7.8 billion in revenue in 2021 and operates in over 100 countries.
Summary not available.
Zoetis (NYSE:ZTS) will participate in the Bank of America Securities 2022 Animal Health Summit on February 24, 2022. Wetteny Joseph, CFO, will present at 2:30 p.m. ET, answering questions from analysts. The event will be accessible via a live audio webcast, available at investor.zoetis.com/events-presentations, with a replay provided afterwards. Zoetis is a leader in animal health, generating $7.8 billion in revenue in 2021, with innovations in medicines and diagnostics serving over 100 countries.
For Q4 2021, Zoetis reported $2.0 billion in revenue, marking a 9% increase year-over-year. Net income rose to $414 million or $0.87 per diluted share. For the full year, revenue reached $7.8 billion, a 16% growth, with net income at $2.0 billion or $4.27 per share. Zoetis anticipates 2022 revenues between $8.325 billion to $8.475 billion, projecting operational growth of 9% to 11%. The company achieved significant sales growth in its companion animal products, despite declines in livestock products due to competition and pricing pressures.
Zoetis Inc. (NYSE:ZTS) has announced a quarterly dividend of $0.325 per share, set for payment on June 1, 2022. This dividend will be distributed to all stockholders on record as of April 21, 2022. With a strong revenue of $6.7 billion in 2020, Zoetis stands as a leader in animal health, providing innovative solutions worldwide. This financial return reflects Zoetis's commitment to its shareholders and reinforces its robust market position.
Zoetis Inc. (NYSE:ZTS) announced FDA approval for Solensia™, the first injectable monoclonal antibody treatment for feline osteoarthritis (OA) pain. This once-monthly injection targets Nerve Growth Factor (NGF), effectively controlling OA pain and enhancing feline mobility and well-being. Studies show that 77% of cat owners observed improved pain signs in their cats after treatment. With nearly 40% of cats affected by OA, Solensia addresses a crucial need in veterinary care. It is anticipated to be available to veterinarians in the second half of 2022.
Zoetis (NYSE:ZTS) announced its commitment to achieving carbon neutrality in its operations by 2030. The initiative includes transitioning to 100% renewable energy, highlighted by a virtual power purchase agreement with Vesper Energy to supply 33% of its North American operational energy needs. Currently, 9 out of 28 manufacturing sites and several offices are already using 100% renewable electricity. Zoetis aims to enhance energy efficiency and transparency regarding emissions, reinforcing its sustainability leadership in animal health.
Zoetis (NYSE:ZTS) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022. CEO Kristin Peck is scheduled to present at 1:30 p.m. ET and will answer questions from analysts. Interested investors can access a live audio webcast of the presentation at http://investor.zoetis.com/events-presentations, with a replay available afterward. Zoetis is a leading animal health company with a revenue of $6.7 billion in 2020, supporting animal care globally.
Zoetis Inc (NYSE:ZTS) will host a webcast and conference call on Feb. 15, 2022, at 8:30 a.m. (ET) to discuss fourth quarter and full year 2021 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and answer questions from analysts. Investors can access the live event on the Zoetis website, with a replay available later that day. Zoetis, a leading animal health company, generated $6.7 billion in revenue in 2020 and operates in over 100 countries, focusing on innovation in animal care.